Age-specific prevalence of HPV16/18 genotypes in cervical cancer: A systematic review and meta-analysis
A partir d'une revue systématique de la littérature publiée entre1999 et 2015 (15 articles, 11 526 cas), cette méta-analyse évalue la prévalence d'une infection par le papillomavirus de type 16 et 18, en fonction de l'âge des patientes atteintes d'un cancer du col de l'utérus
The prevalence of HPV16/18 in cervical cancer has been reported to decline with age in some papers. However, whether this decline in proportion of cancers positive for HPV16/18 is consistently observed across studies remains to be elucidated. Thus, the aim of this study was to identify papers reporting data on age-specific prevalence of HPV16/18 in cervical cancer and to summarize the results. We employed MEDLINE and Embase for a systematic literature search and thereby identified a total of 644 papers published in the period 1999–2015, of which 15 papers, reporting cross-sectional data, were included for review (11,526 cervical cancers). The prevalence of HPV16/18 in cervical cancer declined significantly with age (ρ = −0.83, p = 0.04) from 74.8% (95% CI 67.6–80.8) in women aged 30–39 years to 56.8% (95% CI 43.9–68.8) in women aged ≥70 years. As the HPV16/18 positive cancers are prevented in fully vaccinated cohorts, the age-specific epidemiology of cervical cancer is anticipated to change, with a shift in peak incidence rate to older ages. It will be important for integrated vaccination and screening strategies to consider predicted change in the age-specific epidemiology of cervical cancer.